IFx-Hu2.0
Phase 3Biologic
IFx-Hu2.0 is one of 10 biologic programs targeting Merkel Cell Carcinoma. It is currently in Phase 3.
1
Indications
6
Total Trials
2
Active Trials
9
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
9 competitors in Merkel Cell Carcinoma
#DrugCompanyPhaseTrials
1Keytruda
Merck & Co.Phase 3
Opdivo
Bristol-Myers SquibbPhase 2
Dostarlimab
IncytePhase 2
Lenvima
EisaiPhase 2
Bavencio
EMD SeronoPhase 2
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 2
Vepesid
AAvyxa
Phase 2
Radiation Therapy
MM.D. Anderson Cancer Center
Phase 2
IFx-Hu2.0
TTuHURA Biosciences, Inc.
Phase 3
LIBTAYO
RegeneronPhase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Merkel Cell Carcinoma2 trials
Skin Cancer2 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for IFx-Hu2.0. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 3[1]
- Company
- TTuHURA Biosciences, Inc.